Antihypertensive and target-organ protective properties of telmisartan and hydrochlorothiazide single-pill combination [Антигипертензивные и...
Остроумова О. Д., Кочетков А. И.
Рациональная фармакотерапия в кардиологии
Т. 15, Вып. 4, С. 558-567
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.20996/1819-6446-2019-15-4-558-567
Аннотация:
The most important result of the revision of the European and Russian guidelines for the management of arterial hypertension (AH) was a special focus on initializing antihypertensive treatment with single-pill combinations (SPCs) in majority patients with AH. Combination of the angiotensin II receptor blocker and thiazide diuretic is one of the possible first line SPCs in the absence of specific clinical conditions according to the new guidelines. In this regard, SPC of telmisartan and hydrochlorothiazide (HCT), worth special noticing in the classes of sartans and thiazide diuretics, since both drugs have a long clinical experience and large body of evidence of antihypertensive efficacy and safety, as well as telmisartan also has a number of superior target-organ protective and metabolic properties distinguishing it from other members of the class. In real clinical practice TANDEM study telmisartan and its SPC with HCT showed high antihypertensive efficacy and good tolerability in pati
Ключевые слова:
Antihypertensive treatment; Arterial hypertension; Cardiovascular risk; Clinical guidelines; Hydrochlorothiazide; Metabolic profile; Single-pill combinations of antihypertensive drugs; Target-organ protection; Telmisartan
carbohydrate; cholesterol; glucose; hydrochlorothiazide; insulin; lipid; low density lipoprotein cholesterol; protective agent; telmisartan; triacylglycerol; antihypertensive therapy; Article; atherosclerosis; blood pressure measurement; blood pressure regulation; cardiovascular risk; cholesterol blood level; disease course; drug efficacy; drug mechanism; drug safety; drug tolerability; glucose blood level; heart protection; human; hypertension; hypertensive patient; lipid fingerprinting; long term care; pharmacological parameters; pill; target organ
Язык текста: Русский
ISSN: 2225-3653
Остроумова О. Д. Ольга Дмитриевна 1968-
Кочетков А. И.
Ostroumova O. D. Ol`ga Dmitrievna 1968-
Kochetkov A. I.
Antihypertensive and target-organ protective properties of telmisartan and hydrochlorothiazide single-pill combination [Антигипертензивные и органопротективные свойства фиксированной комбинации телмисартана и гидрохлоротиазида]
Antihypertensive and target-organ protective properties of telmisartan and hydrochlorothiazide single-pill combination [Антигипертензивные и...
Текст визуальный непосредственный
Рациональная фармакотерапия в кардиологии
Столичная издательская компания
Т. 15, Вып. 4 С. 558-567
2019
Статья
Antihypertensive treatment Arterial hypertension Cardiovascular risk Clinical guidelines Hydrochlorothiazide Metabolic profile Single-pill combinations of antihypertensive drugs Target-organ protection Telmisartan
carbohydrate cholesterol glucose hydrochlorothiazide insulin lipid low density lipoprotein cholesterol protective agent telmisartan triacylglycerol antihypertensive therapy Article atherosclerosis blood pressure measurement blood pressure regulation cardiovascular risk cholesterol blood level disease course drug efficacy drug mechanism drug safety drug tolerability glucose blood level heart protection human hypertension hypertensive patient lipid fingerprinting long term care pharmacological parameters pill target organ
The most important result of the revision of the European and Russian guidelines for the management of arterial hypertension (AH) was a special focus on initializing antihypertensive treatment with single-pill combinations (SPCs) in majority patients with AH. Combination of the angiotensin II receptor blocker and thiazide diuretic is one of the possible first line SPCs in the absence of specific clinical conditions according to the new guidelines. In this regard, SPC of telmisartan and hydrochlorothiazide (HCT), worth special noticing in the classes of sartans and thiazide diuretics, since both drugs have a long clinical experience and large body of evidence of antihypertensive efficacy and safety, as well as telmisartan also has a number of superior target-organ protective and metabolic properties distinguishing it from other members of the class. In real clinical practice TANDEM study telmisartan and its SPC with HCT showed high antihypertensive efficacy and good tolerability in pati